Compositions and methods for treatment of symptoms in parkinson's disease patients
AssigneeParkinson's Institute
InventorArasteh Ari AZHIR
Life of this patent
Estimating the term…
Abstract
The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.
Claims22
A pulsatile release dosage form for twice-daily administration, said form comprising a capsule or tablet comprising an effective amount of nicotine for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease, wherein said capsule or tablet exhibits pulsatile release of said nicotine.
A delayed release dosage form for twice-daily administration, said form comprising a liquid filled capsule comprising an effective amount of nicotine for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease, wherein said capsule comprises a hard gelatin outer surface.
-17. (canceled)
An extended release dosage form for once-daily administration, said form comprising a capsule or tablet comprising an effective amount of nicotine for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease, wherein said capsule or tablet achieves an efficacious plasma concentration of nicotine or a metabolite thereof within one hour from administration for a duration of at least six hours and further wherein said capsule or tablet achieves a peak plasma concentration of nicotine or a metabolite thereof at least about two hours after administration.
-40. (canceled)
A method of treating gait and balance problems in a subject, comprising administering an oral composition comprising nicotine, wherein the gait and balance problems are direct symptoms of Parkinson's Disease.
-50. (canceled)
Dependencies are inferred from the claim text.